US Congress House Bill 2148

---

Spectrum: Partisan Bill (Democrat 19-0)
Status: Introduced on March 23 2021 - 25% progression
Action: 2021-10-19 - Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.
Pending: House Subcommittee on Antitrust, Commercial, and Administrative Law Committee
Text: Latest bill text (Introduced) [PDF]

Establishes a series of oversight and disclosure requirements relating to the prices of brand-name drugs. Specifically, the bill requires the Department of Health and Human Services (HHS) to review at least annually all brand-name drugs for excessive pricing; HHS must also review prices upon petition. If any such drugs are found to be excessively priced, HHS must (1) void any government-granted exclusivity; (2) issue open, nonexclusive licenses for the drugs; and (3) expedite the review of corresponding applications for generic drugs and biosimilar biological products. HHS must also create a public database with its determinations for each drug. Under the bill, a price is considered excessive if the domestic average manufacturing price exceeds the median price for the drug in Canada, the United Kingdom, Germany, France, and Japan. If a price does not meet this criteria, or if pricing information is unavailable in at least three of the aforementioned countries, the price is still considered excessive if it is higher than reasonable in light of specified factors, including development cost, revenue, and the size of the affected patient population. The bill also requires drug manufacturers to report specified financial information for brand-name drugs, including research and advertising expenditures.

Prescription Drug Price Relief Act of 2021

Rep. Ro Khanna [D-CA]	Rep. Jamaal Bowman [D-NY]	Rep. Peter DeFazio [D-OR]	Rep. Rosa DeLauro [D-CT]
Rep. Pramila Jayapal [D-WA]	Rep. Mondaire Jones [D-NY]	Rep. Barbara Lee [D-CA]	Rep. Joseph Neguse [D-CO]
Rep. Eleanor Norton [D-DC]	Rep. Alexandria Ocasio-Cortez [D-NY]	Rep. Ilhan Omar [D-MN]	Rep. Mark Pocan [D-WI]
Rep. Ayanna Pressley [D-MA]	Rep. Jamie Raskin [D-MD]	Rep. Janice Schakowsky [D-IL]	Rep. Rashida Tlaib [D-MI]
Rep. Peter Welch [D-VT]	Rep. Cori Bush [D-MO]	Rep. Mark DeSaulnier [D-CA]

Date	Chamber	Action
2021-10-19	House	Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.
2021-03-24	House	Referred to the Subcommittee on Health.
2021-03-23	House	Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
2021-03-23	House	Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
2021-03-23	House	Introduced in House

SB909 (Same As) 2021-03-23 - Committee on Health, Education, Labor, and Pensions Subcommittee on Primary Health and Retirement Security. Hearings held.

Type	Source
Summary	https://www.congress.gov/bill/117th-congress/house-bill/2148/all-info
Text	https://www.congress.gov/117/bills/hr2148/BILLS-117hr2148ih.pdf